This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Galunisertib

Eli Lilly & Company

Drug Names(s): LY2157299, 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate

Description: LY2157299 is an inhibitor of TGF-beta receptor 1 kinase. TGF-beta overexpression affects the tumor microenvironment by decreasing immune surveillance, increasing tumor invasiveness and metastatic potential, and enhancing angiogenesis.


Galunisertib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug